Skip to main
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 45%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is a surgical robotics company with a positive outlook due to its innovative solutions and focus on advancing patient care. Though there may be some short-term challenges in reaching their projected procedure numbers, the company is well-positioned for long-term success with its strong product line and expanding presence in both the US and international markets. Additionally, the recent increase in PAE reimbursement highlights the potential for further growth in the future.

Bears say

PROCEPT BioRobotics is facing several headwinds that could hinder its ability to achieve sustainable growth in the future. These include (1) a slowdown in procedure growth due to increased adoption of a competing procedure with higher profit margins, (2) a restructured sales force under new leadership with uncertain effectiveness, (3) potential headwinds from an upcoming increase in competition in the market for BPH treatment, and (4) potential pricing pressure and challenges with gaining favorable reimbursement. While the company has achieved growth in recent sales, these challenges raise concerns about its future performance and make it difficult for the stock to break out of its current trading range. As such, the analyst has a negative outlook on PROCEPT BioRobotics stock and has lowered their price target to $30.

PRCT has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 11 analysts, PRCT has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.